Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of May 2022. The report, dated May 11, 2022, serves to disseminate a press release (Exhibit 99.1) to U.S. investors. The company is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods. The content is limited to the submission of a press release dated May 11, 2022.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or details on unusual items. The substantive content of the press release referenced in Exhibit 99.1 is not included in the provided text.
Key Facts for Investor Verification
- Verify the full content of the press release dated May 11, 2022, referenced as Exhibit 99.1, as the filing text itself contains no operational or financial details.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that the report was signed by Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.